Researchercts CaritasKlinikum SaarbrückenActive in the last 2 years
Manfred Paul Lutz
Matched on ORCID iD 0000-0003-1989-4553; OpenAlex author ID A5066686378. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 3, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 93
2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 13
- Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). Co-author DOI 10.1038/s41416-025-03188-x↗
- An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. First author DOI 10.1186/s12943-025-02406-7↗
- Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
- Early Detection of Pancreatic Cancer. Last author DOI 10.1159/000530790↗
- Incidence and relative survival of pancreatic adenocarcinoma and pancreatic neuroendocrine neoplasms in Germany, 2009-2018. An in-depth analysis of two populat… Co-author DOI 10.1016/j.canep.2022.102204↗
- Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Co-author DOI 10.1186/s12885-019-5889-5↗
- Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. First author DOI 10.1159/000488917↗
- 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
- Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000000389↗
- Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
- [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
- New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Last author DOI 10.1093/annonc/mdr351↗
- Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Last author DOI 10.1093/annonc/mdr379↗
Closest collaborators
The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thomas Jens Ettrich · 3 shared papers, 2023–2026 · strength 0.53
- Paper Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced panc… DOI 10.1038/s41416-025-03188-x↗
- Paper An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: les… DOI 10.1186/s12943-025-02406-7↗
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Meinolf Karthaus · 2 shared papers, 2025–2026 · strength 0.41
- Paper Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced panc… DOI 10.1038/s41416-025-03188-x↗
- Paper An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: les… DOI 10.1186/s12943-025-02406-7↗
- Thomas Theodor Werner Seufferlein · 3 shared papers, 2017–2025 · strength 0.36
- Paper An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: les… DOI 10.1186/s12943-025-02406-7↗
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the prima… DOI 10.1016/j.ejca.2017.03.022↗
- Phyllis F. Cheung · 2 shared papers, 2018–2025 · strength 0.33
- Jens Thomas Siveke · 2 shared papers, 2018–2025 · strength 0.33
- Andrea Tannapfel · 2 shared papers, 2023–2025 · strength 0.31
- Paper An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: les… DOI 10.1186/s12943-025-02406-7↗
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Alexander Kleger · 2 shared papers, 2023–2025 · strength 0.31
- Paper An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: les… DOI 10.1186/s12943-025-02406-7↗
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Jérôme Schwingel · 1 shared paper, 2023 · strength 0.24
- Ruben R. Plentz · 1 shared paper, 2026 · strength 0.22
- Dirk Waldschmidt · 1 shared paper, 2026 · strength 0.22
- Rui Fang · 1 shared paper, 2025 · strength 0.19
- Tim Eiseler · 1 shared paper, 2025 · strength 0.19
- Anton Lahusen · 1 shared paper, 2025 · strength 0.19
- Albrecht Stenzinger · 1 shared paper, 2025 · strength 0.19
- Michel Pierre Ducreux · 4 shared papers, 2012–2019 · strength 0.19
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the prima… DOI 10.1016/j.ejca.2017.03.022↗
- Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
- Andreas Stang · 1 shared paper, 2022 · strength 0.17
- Hiltraud Kajüter · 1 shared paper, 2022 · strength 0.17
- Jean‐Luc Van Laethem · 3 shared papers, 2012–2019 · strength 0.17
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the prima… DOI 10.1016/j.ejca.2017.03.022↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Waldemar H. Uhl · 2 shared papers, 2012–2023 · strength 0.14
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. DOI 10.1093/annonc/mdr351↗
- Eike Gallmeier · 1 shared paper, 2023 · strength 0.12
- Jasmin Schuhbaur · 1 shared paper, 2023 · strength 0.12
- Michael B. Ghadimi · 1 shared paper, 2023 · strength 0.12
- Volker Kunzmann · 1 shared paper, 2023 · strength 0.12
- Michael Geißler · 1 shared paper, 2023 · strength 0.12
- Ingo Klein · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.